Ensysce Biosciences posts $3.7 million net loss for Q3 2025

Reuters11-15

Ensysce Biosciences posts $3.7 million net loss for Q3 2025

Ensysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583319684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583319684","market":"us","top_or_hot":-1,"title":"Ensysce Biosciences posts $3.7 million net loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences posts $3.7 million net loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences posts $3.7 million net loss for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENSC","symbol_name":"Ensysce Biosciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL7jdrf5:1","article_id":"2583319684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583319684","pubTimestamp":1763154923,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENSC":"Ensysce Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Ensysce Biosciences公布2025年第三季度净亏损370万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    \n\nEnsysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583319684","isCrawlerRequest":true}